Binding agent, polynucleotide sequence, expression vector, host cell, pharmaceutical composition, and methods of inhibiting myostatin activity, increasing lean muscle mass and lean to fat ratio, treating muscle wasting disease is a myostatin-related metabolic disorder in an individual, detecting and measuring myostatin in a sample, and diagnosing a myostatin-related disorder in an individual

摘要

"BINDING AGENT, POLYNUCLEOTIDE SEQUENCE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, AND METHODS OF INHIBITING MIOSTATIN ACTIVITY, MASSCULAR MASSARRA MASSAGE TO A MASSAR CRACLE MUSCULAR AND A MYOSTATIN-RELATED METABOLIC DISORDER IN AN INDIVIDUAL OF DETECTING AND MEASURING MYOSTATIN IN A SAMPLE AND DIAGNOSING A MYOSTATIN-RELATED DISORDER IN AN INDIVIDUAL ". The present invention provides binding agents comprising peptides capable of binding to myostatin and inhibiting their activity. In one embodiment the binder comprises at least one myostatin binder peptide directly or indirectly linked to at least one carrier such as a polymer or an Fc domain. The binders of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle wasting disorders and other metabolic disorders including diabetes and obesity.